Origin Agritech (SEED) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
30 Jul, 2026Corporate overview and leadership
Specializes in agricultural biotechnology, focusing on superior crop varieties and advanced breeding techniques.
Holds a leading position in corn germplasm resources in China, with a legacy in hybrid corn breeding since 1997.
Recent leadership transition brought in CEO Weibin Yan, who invested personal capital and implemented a five-pillar turnaround strategy.
The new executive team includes experienced leaders from global agribusiness and capital markets.
Operating loss narrowed by 47.8% and G&A expenses fell 70% year-over-year in 1H FY2026.
Strategic direction and growth plan
Five-pillar turnaround framework: market-oriented breeding, biotech commercialization, sales network rebuilding, supply chain upgrades, and organizational strengthening.
Three-phase strategy: 2024-2026 restructuring, 2026-2029 strong growth, and 2029-2032 international expansion targeting 20% overseas revenue.
Open to strategic partnerships and long-term investments to leverage germplasm, gene-editing, and GMO portfolios.
CEO has a track record of landmark strategic transactions and deep industry relationships.
R&D, innovation, and product pipeline
Operates four research stations across China, focusing on seed R&D and collaborative partnerships.
Advanced seed production base in Xinjiang with modern mechanization and processing capacity of 60,000 tons/year.
Strong alliances with top Chinese agricultural research institutions for co-breeding and gene-editing projects.
Robust pipeline with multiple breeding programs and 112 hybrids approved as new varieties over 27 years.
National recognition for gene-editing breakthroughs, including the Hi3 platform and new alleles for earlier maturity.
Latest events from Origin Agritech
- Driving China's agricultural modernization with gene-edited, high-yield GMO corn and NEC products.SEED
Corporate presentation25 May 2026 - Revenue fell on portfolio shift, but net loss narrowed and new financing supports future growth.SEED
Q2 202622 May 2026 - Revenue fell 90% in 2025, but strategic moves and financing support future growth.SEED
Q4 20252 Feb 2026 - Biotech seed firm with VIE structure plans $30M shelf offering amid regulatory and financial risks.SEED
Registration Filing2 Feb 2026 - Biotech seed firm targets $30M raise amid regulatory shifts and ongoing financial volatility.SEED
Registration Filing2 Feb 2026 - Biotech seed firm targets $30M raise amid regulatory, VIE, and financial risks in China.SEED
Registration Filing2 Feb 2026